Calidi Biotherapeutics CLDI
NYSE CLDI
$0.68 -0.02 (-2.86%)
At close: Nov 11, 2026 · 4:00 PM EST

Calidi Biotherapeutics (CLDI) Net Income Attributable to Noncontrolling Interests (2024 - 2025)

Updated

Calidi Biotherapeutics (CLDI) reported Income from Non-Controlling Interests of -$3,000 for Q4 2025, compared with -$51,000 a year earlier.

Analysis

Calidi Biotherapeutics (CLDI) Net Income Attributable to Noncontrolling Interests (2024 - 2025) Analysis & Trends

For FY2025, Calidi Biotherapeutics posted Income from Non-Controlling Interests of -$157,000.

  • By year, Income from Non-Controlling Interests came in at -$66,000 in FY2024.
  • Per Business Quant data, the three quarters before Q4 2025 came in at -$32,000 (Q3 2025), -$46,000 (Q2 2025) and -$76,000 (Q1 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) NCI Net Income (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn -
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn -
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn 2.00 Mn
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn 2.00 Mn
5 Novartis Ag 311.58 Bn 285.16 Bn - -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn -1.00 Mn
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn -
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn -
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn 10.00 Mn
10 Calidi Biotherapeutics 991,199.98 -25.74 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2025 -3,000.00
Sep 30, 2025 -32,000.00
Jun 30, 2025 -46,000.00
Mar 31, 2025 -76,000.00
Dec 31, 2024 -51,000.00
Sep 30, 2024 -15,000.00
API Access

Calidi Biotherapeutics Net Income Attributable to Noncontrolling Interests API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=income-from-non-controlling-interests&ticker=CLDI&period=max&api_key=YOUR_API_KEY